EverHint Lens - United Therapeutics Corporation ($UTHR) - Yahoo Finance Top Gainer (+13%) Stock Analysis - March 30, 2026

Analysis Date: 2026-03-30
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

Executive Summary

United Therapeutics Corporation is currently trading at $594.59 (🟢 +13.73% today) with a market capitalization of $26.06B.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Price & Valuation

Current Price: $594.59 (at 11:08 AM ET)
Current Volume: 673.9K
Day Range: $580.78 - $607.89
52-Week Range: $266.98 - $607.89
P/E Ratio: 19.75

DCF Valuation: Fair Value

• Intrinsic Value (Unlevered DCF): $650.49
• Current Price: $594.59
• Discount/Premium: +9.4%

Levered DCF: $766.43 (+28.9%)

DCF analysis suggests the stock is trading near its intrinsic value (within ±15%).

DCF values calculated as of 2026-03-30. Underlying assumptions are not disclosed by the data provider. Levered vs unlevered can diverge materially for highly levered companies.

Market Context

Healthcare Sector: 0.3121% | Sector P/E: 26.18

Major Indices:

• S&P 500: $6394.02 (🟢 +0.40%)
• NASDAQ Composite: $20981.22 (🟢 +0.16%)
• Dow Jones Industrial Average: $45484.31 (🟢 +0.70%)

Peer Comparison

Peer comparison (11 companies):

• UTHR - United Therapeutics Corporation ($594.59, +13.7%, $26.06B) ← Current
• BIIB - Biogen Inc. ($187.78, +2.1%, $27.56B)
• DGX - Quest Diagnostics Incorporated ($197.16, +0.8%, $21.93B)
• RPRX - Royalty Pharma plc ($46.42, +0.2%, $19.89B)
• ILMN - Illumina, Inc. ($121.20, +3.0%, $18.53B)
• INCY - Incyte Corporation ($91.14, +0.9%, $18.14B)
• WST - West Pharmaceutical Services, Inc. ($246.64, +1.4%, $17.76B)
• ZBH - Zimmer Biomet Holdings, Inc. ($88.88, +0.4%, $17.61B)
• WAT - Waters Corporation ($293.11, +1.4%, $17.44B)
• THC - Tenet Healthcare Corporation ($191.88, +0.0%, $16.86B)
• GMAB - Genmab A/S ($25.96, +0.5%, $16.00B)

Financial Performance

Latest Quarter (2025-12-31):

• Revenue: $790.20M
• Net Income: $364.30M
• EPS: $8.36
• Revenue Growth (QoQ): -1.2%

Stock Split History

UTHR has executed 1 stock split(s) historically

• 2009-09-23: 2-for-1 split

Cumulative Split Factor: 2x (1 share in 1987 = 2 shares today)

Most recent split: 2-for-1 on 2009-09-23

Earnings Calendar

Next Earnings Report: 2026-04-29 (Before Market Open)

• EPS Estimate: $7.01
• Revenue Estimate: $0.80B

Most Recent Report: 2026-02-25

• EPS: $7.70 (Est: $7.13) ✓ Beat
• Revenue: $0.79B

Historical Data: 109 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

• Target: $579.83 (-2.5% upside)
• Range: $447.00 - $645.00
• Median: $593.50

Next Quarter Estimates (2027-12-31):

• Revenue: $923.63M
• EPS: $10.33

Analyst Consensus

Overall Rating: Buy

Rating Distribution (289 total ratings):

• 🟢 Buy/Outperform: 165 (57.1%)
• ⚪ Hold/Neutral: 82 (28.4%)
• 🔴 Sell/Underperform: 28 (9.7%)

Recent Analyst Actions:

• RBC Capital (2025-09-26): Initiate Outperform
• Cantor Fitzgerald (2026-03-12): Maintain Overweight
• Jefferies (2026-03-02): Maintain Buy
• H.C. Wainwright (2026-02-26): Maintain Buy
• Cowen & Co. (2026-02-25): Maintain Buy

Consensus based on 289 analyst ratings from major financial institutions

Trading Signals

Our technical analysis identified 5 trading signal(s) in the last 60 days:

• 2026-03-10: Momentum Swing - breakout @ $535.81
• 2026-03-09: Ema10 Price Macd - EMA10_Price_MACD_Buy @ $529.17
• 2026-03-04: Sma20 Sma50 - SMA20_x_SMA50_Buy @ $490.21
• 2026-02-25: Ema10 Ema30 - EMA10_x_EMA30_Buy @ $535.10
• 2026-02-25: Volatility Squeeze - VOL_SQUEEZE_BREAKOUT_LONG @ $535.10

Insider Activity

Recent Transactions (Last 10):

• Buys: 1
• Sells: 9

Notable Transactions:

• 2026-03-26: ROTHBLATT MARTINE A - Sell (Option Exercise, 9,500 shares @ $146.03)
• 2026-03-26: ROTHBLATT MARTINE A - Buy (Option Exercise, 9,500 shares @ $146.03)
• 2026-03-26: ROTHBLATT MARTINE A - Sell (Sale, 159 shares @ $530.95)

Congressional Trading Activity

Tracking recent stock transactions by U.S. Congress members

House of Representatives: 8 transactions tracked

Recent Activity:

• 🟢 Lisa McClain (MI09): Purchase on 2025-06-11 @ $276.47, Amount: $1,001 - $15,000
• 🔴 Michael McCaul (TX10): Sale on 2023-05-12 @ $214.02, Amount: $100,001 - $250,000
• 🔴 Michael McCaul (TX10): Sale on 2023-05-12 @ $214.02, Amount: $15,001 - $50,000
• 🟢 Michael McCaul (TX10): Purchase on 2022-03-01, Amount: $1,001 - $15,000
• 🟢 Michael McCaul (TX10): Purchase on 2022-03-01, Amount: $15,001 - $50,000

Congressional trading data sourced from official disclosure filings

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

News sentiment for United Therapeutics Corporation (UTHR) is overwhelmingly positive, fueled by successful TETON-1 and TETON-2 clinical trials meeting endpoints for IPF treatment, strong Q4 earnings beating estimates with robust Tyvaso sales, and a $2 billion stock repurchase authorization. Stock surges, analyst upgrades, and institutional interest further bolster optimism, despite minor insider selling. These developments position UTHR for growth in PAH and IPF markets.

Key Themes:

• Clinical Trial Successes
• Strong Earnings and Buybacks
• Stock Price Momentum

Sentiment: Positive (95% confidence)

Reddit Sentiment

Community Discussion (last 30 days from r/wallstreetbets, r/stocks, r/investing):

Overall Sentiment: Strongly Bullish 📈📈 (Score: 0.995)

Post Analysis:

• Total posts: 1
• Bullish: 1 (100.0%)
• Bearish: 0 (0.0%)
• Neutral: 0 (0.0%)
• Total engagement: 195 (upvotes + comments)

Note: Sentiment score ranges from -1.0 (very bearish) to +1.0 (very bullish), weighted by post engagement.

Recent News

5 most recent articles covering UTHR:

• United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2 (businesswire.com, 2026-03-30) — Read more
• United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue? (zacks.com, 2026-03-27) — Read more
• NorthCrest Asset Manangement LLC Purchases 1,843 Shares of United Therapeutics Corporation $UTHR (defenseworld.net, 2026-03-23) — Read more
• Two Biotech Stocks Hover Near Highs; Natural Gas And Finance Names Show Resilience (investors.com, 2026-03-20) — Read more
• United Therapeutics (NASDAQ:UTHR) CEO Sells $5,072,050.00 in Stock (defenseworld.net, 2026-03-20) — Read more

Full news analysis based on 30 recent articles

Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-03-30 08:08:59 AM PDT

Disclaimer: This is not investment advice. Always do your own research before making investment decisions.